Robert F. Williamson III Buys 6,266 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III bought 6,266 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average price of $3.64 per share, with a total value of $22,808.24. Following the completion of the acquisition, the director now directly owns 430,058 shares of the company’s stock, valued at $1,565,411.12. This represents a 1.48 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $4.12 on Thursday. Perspective Therapeutics, Inc. has a one year low of $2.28 and a one year high of $19.05. The business’s 50-day simple moving average is $10.96.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. Equities analysts expect that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Truist Financial assumed coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer dropped their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday. Finally, UBS Group started coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.14.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently modified their holdings of the stock. nVerses Capital LLC purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at $57,000. US Bancorp DE boosted its position in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Intech Investment Management LLC purchased a new position in Perspective Therapeutics in the third quarter valued at about $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Perspective Therapeutics in the 3rd quarter worth about $152,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter worth about $153,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.